Monday, October 5, 2026

Skild AI's $1.4B Raise Leads Robotics Funding Surge Powered by AI Foundation Models

Robotics startups raised billions at early stages in 2026, with Skild AI, Mind Robotics, Neura Robotics, and others commanding valuations once reserved for mature companies. AI foundation models — trained on broad, unstructured data — have narrowed the core engineering bottleneck blocking general-purpose robots. Investors appear to be pricing commercial viability by 2027-2028.

LM Salvado

June 27, 2026

Skild AI's $1.4B Raise Leads Robotics Funding Surge Powered by AI Foundation Models
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Skild AI raised $1.4B in January 20261 — ten times its $135M Series B from just months earlier. The jump signals a broader pattern: AI foundation models have changed the calculus for robotics investment.

Mind Robotics closed a $500M Series A in March2, then added a $400M follow-on in May3. Neura Robotics secured up to $1.4B in a Series C in June4. Shihang Intelligent raised $1B at Series A stage that same month5.

Billion-dollar valuations at Series A and B are the telling detail. Early-stage companies typically raise tens of millions, not hundreds. Investors are pricing in the assumption that AI-driven robots will reach commercial viability by 2027-2028.

Apptronik extended its Series A with $520M in February 20266, building on its $415M raise in 2025. Saronic, developing autonomous maritime vessels, closed a $1.75B Series D in March7.

Foundation models trained on diverse, unstructured data let robots generalize across tasks. Earlier robotics systems required expensive per-task programming. That bottleneck has narrowed as model capabilities have scaled — and capital is following the shift.

M&A is accelerating alongside the funding. Meta acquired Assured Robot Intelligence in May 20268. Skild AI acquired Zebra Technologies' Robotics Division in April9, expanding its enterprise deployment footprint shortly after its own mega-round closed.

For the broader AI sector, robotics is now the clearest near-term path from model capabilities to physical-world revenue. The companies holding this capital face the harder test: consistent performance outside controlled environments, at the scale needed to justify these valuations.

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com